Oral Low-Dose Ferric Citrate Is a Useful Iron Source for Hyperphosphatemic Hemodialysis Patients: A Case Series

Publisher： Karger

E-ISSN： 1421-9735|43|1-3|97-100

ISSN： 0253-5068

Source： Blood Purification, Vol.43, Iss.1-3, 2016-12, pp. : 97-100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intravenous Low-Dose Iron Administration in Hemodialysis Patients Treated with Erythropoietin

By  

Nephron, Vol. 80, Iss. 3, 1998-11 ,pp. : 369-370

Karger

Access to resources Recommend Favorite

Intravenous Low-Dose Iron Administration in Hemodialysis Patients Treated with Erythropoietin: 1-Year Follow-Up Study

By  

Nephron, Vol. 86, Iss. 2, 2000-09 ,pp. : 200-201

Karger

Access to resources Recommend Favorite

Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency

By  

Nephron, Vol. 131, Iss. 3, 2015-0 ,pp. : 161-166

Karger

Access to resources Recommend Favorite

Refeeding Hypophosphatemia in a Chronically Hyperphosphatemic Hemodialysis Patient

By  

Nephron, Vol. 86, Iss. 4, 2000-12 ,pp. : 552-552

Karger

Access to resources Recommend Favorite

Randomized Controlled Trial to Evaluate Regional Citrate Anticoagulation Plus Low-Dose of Dalteparin in Continuous Veno-Venous Hemofiltration

By  

Blood Purification, Vol. 39, Iss. 4, 2015-05 ,pp. : 306-312

Karger

Access to resources Recommend Favorite